| Study Summary: |
|
OBJECTIVES:
Primary
- To quantify the difference in memory impairment (via psychometrically validated
computerized CANTAB test) in breast cancer (females receiving anthracycline and
non-anthracycline regimens) or lymphoma patients (males and females receiving
chemotherapy) compared with a control comparison group of the same age and gender at
pre-treatment and post-treatment.
Secondary
- To quantify the difference in verbal memory impairment (via psychometrically validated
computerized CANTAB test) in breast cancer (females receiving anthracycline and
non-anthracycline regimens) and lymphoma patients (males and females receiving
chemotherapy) compared with a control comparison group of the same age and gender at
pre-treatment and post-treatment.
- To quantify the difference in executive function impairment (via psychometrically
validated computerized CANTAB test) in breast cancer (females receiving anthracycline
and non-anthracycline regimens) and lymphoma patients (males and females receiving
chemotherapy) compared with a control comparison group of the same age and gender at
pre-treatment and post-treatment.
- To quantify the difference in attention impairment (via psychometrically validated
computerized CANTAB test) in breast cancer (females receiving anthracycline and
non-anthracycline regimens) and lymphoma patients (males and females receiving
chemotherapy) compared with a control comparison group of the same age and gender at
pre-treatment and post-treatment.
Tertiary
- To quantify the difference in memory, executive function, and attention impairments at
six-month follow-up in breast cancer and lymphoma patients compared to a control
comparison group of the same age and gender at pre-treatment and post-treatment.
(Exploratory)
- To quantify the difference in memory, executive function, and attention impairments by
validated standard neuropsychological testing and phone-based cognitive assessments.
(Exploratory)
- To quantify the difference in memory, executive function, and attention impairments by
single item self-report questions, and validated self-report instruments (i.e.,
BRIEF-A, FACT-Cog). (Exploratory)
- To identify the relationships between performance on self-report, phone-based cognitive
testing, standard neuropsychological testing, and computerized CANTAB testing in breast
cancer and lymphoma patients compared with a control comparison group of the same age
and gender at pre-treatment, post-treatment, and at six-month follow-up. (Exploratory)
- To provide data on the associations of inflammatory molecules (i.e., IL-6, MCP-1, IL-8,
IL-1β, PGE2) with cognitive functioning in breast cancer and lymphoma patients compared
with a control comparison group of the same age and gender at pre-treatment,
post-treatment, and at six-month follow-up. (Exploratory)
- To provide data on the associations of SNPs (e.g. APOE, COMT, MRE) with cognitive
functioning in breast cancer and lymphoma patients compared with a control comparison
group of the same age and gender at pre-treatment, post-treatment, and at six-month
follow-up. (Exploratory)
OUTLINE: This is a multicenter study.
Patients and controls are assessed for memory, executive functions, and attention using the
Cambridge Neuropsychological Test Automated Battery (CANTAB) computerized testing, the Wide
Range Achievement Test-Third Edition (WRAT-4), the Hopkins Verbal Learning and Memory
Test-Revised (HVLT-R), the Trail Making Test (Comprehensive Trail Making Test Trails 1 and
5), the Controlled Oral Word Association Test (COWA), the Functional Assessment of Cancer
Therapy with Cognition (FACT-Cog), and the MD Anderson Symptom Inventory at baseline, within
1 month after completion of therapy, and then after 6 months. Patients and controls also are
assessed by telephone and self-report symptoms on quality of life, anxiety, fatigue, sleep,
and physical activity. Demographics and clinical data are also collected.
Serum, plasma and whole blood samples are collected for correlative studies.
|